Introduction {#s1}
============

We recently found that Lactic acidosis could effectively protect cancer cells against glucose starvation or deprivaiton ([@bib33]; [@bib34]). First, lactic acidosis dramatically reduces glycolysis rate with little wasting glucose to lactate, as such, a limited amount of glucose could support cancer cells for a relatively long time otherwise would be exhausted quickly. Second, when glucose was deprived, lactic acidosis transformed cancer cells to a 'dormant' state, via arresting cells at G0/G1 phase, initiating autophagy, inhibiting apoptosis, etc. The protective function relies on co-presence of lactate and proton, depriving either of which would abolish the function ([@bib33]; [@bib34]). When converting lactic acidosis to lactosis by a base, the protective function is gone; similarly, removing lactate, acidosis conferred cancer cells with little resistance to glucose deprivation.

The significance of intratumoral lactic acidosis in tumor biology has been extensively revealed by many other investigators. Clinical studies showed that high level of lactate was a strong prognostic indicator of increased metastasis and poor overall survival ([@bib8]; [@bib1]; [@bib32]; [@bib25]; [@bib31]; [@bib35]; [@bib21]). The work of Gillies and Gatenby group demonstrated that systematic and tumor pHe alkalization could inhibit carcinogenesis, tumor invasion and metastasis, and they also provided integrated models that can predict the safety and efficacy of buffer therapy to raise tumour pHe ([@bib28]; [@bib24]; [@bib11]) and related theoretical work ([@bib19], [@bib18]). Furthermore, many studies reported that lactic acidosis played multifaceted roles in skewing macrophages ([@bib4]) and inhibiting the function of cytotoxic T cells ([@bib10]), altering cancer cell metabolism ([@bib3]; [@bib29]), inducing chromosomal instability ([@bib5]), and promoting tumor angiogenesis ([@bib8]; [@bib30]).

According to the guideline of Barcelona Clinic Liver Cancer (BCLC) staging and treatment strategy, HCC larger than 3 cm in diameter is not suitable for curative therapy (surgical resection, liver transplantation, and ablation) and the recommended treatment is TACE ([@bib7]; [@bib6]; [@bib16]). But sadly, it is recognized that TACE is not effective to treat large tumors ([@bib27]). This leaves the patients with large HCC without choice of effective therapy, as also pointed out by Sieghart et al, "maximal restriction of patients selection for TACE would otherwise only improve the results of the treatment modality per se but again would leave those more advanced patients within the intermediate stage without treatment options." ([@bib27])

TACE is for local control of the targeted tumor. $T E X\ \text{equation\ check}$TACE kills HCC via 2 mechanisms, delivering concentrated anticancer drugs locally into tumor and occluding tumor feeding arteries to deprive nutrients to starve cancer cells. We would focus on the second mechanism. Occluding tumor feeding arteries effectively deprive nutrients including glucose. The problem is that embolization-created hypoxia condition would stimulate cancer cells to emit strong signals to initiate angiogenesis ([@bib16]) to reestablish tumor vasculature to bypass the occluded tumor feeding arteries. If the tumor cells cannot be rapidly eliminated, tumor vasculature would be re-established, and a certain amount of tumor (ranging from a few percent of the original tumor to even a larger tumor known as progressive disease) would survive and thrive. The lactate concentrations in HCC biopsies were around 20 mM (unpublished data), suggesting a lactic acidosis condition. After TACE, lactic acidosis would be trapped in embolized tumor and it would potentially attenuate the therapeutic efficacy of TACE. If it were true, locally infusion of bicarbonate to neutralize it would result in a severer necrosis in the embolized area.

Results {#s2}
=======

Local control of targeted large tumors as assessed by viable tumor residues (VTR) {#s2-1}
---------------------------------------------------------------------------------

TACE is to control the targeted tumors rather than to systematically control the disease. As such, to measure the necrosis of the targeted tumors can quantitatively reflect the therapeutic efficacy of TACE. It is known that large size of HCC is a major obstacle to limit the therapeutic efficacy of TACE ([@bib27]), the larger the tumor size, the poorer the efficacy of TACE. Thus, the large HCC is a perfect tumor model to test our hypothesis. If intratumoral lactic acidosis is responsible for the therapeutic limitation, locally neutralizing it should significantly improve the anticancer activity, which can be quantitatively measured by the viable tumor residues. To the best of our knowledge, assessment of the necrosis of tumor after the first treatment is probably most objective with least interferences of known and unknown factors. Unless otherwise indicated, the data presented below are the response to the first TACE treatment.

We retrieved 27 patients with large HCC (ranging 5.0--14.6 cm) from the pool of patients treated with cTACE in the hospital between 2010 and 2012 according to the inclusion and exclusion criteria as specified in the Materials and methods section. The amount of viable tumor residues after cTACE treatment was calculated. We then recruited 30 patients for the TILA-TACE group using the same inclusion and exclusion criteria between 2012 and 2013. Most of patients' demographic and clinicopathologic characteristics between the two treatment groups cTACE and TILA-TACE were generally comparable (Table 1). However, patients in the cTACE group were more likely to have multifocal tumors.

###### Clinical and tumor characteristics of patients treated with cTACE and TILA-TACE in the nonrandomized study.

  Variables                                    Patients                
  -------------------------------------------- ----------------------- ------------------------
  Patient number                               30                      27
  Median age, years                            57 (Range 32--81)       54 (Range 37--81)
  Gender (M/F)                                 27/3 (90.0%/10.0%)      27/0 (100%/0%)
  Aetiology                                                            
   HBV                                         24 (80.0%)              25 (92.6%)
   HCV                                         0 (0%)                  0 (0%)
   Non B-non C                                 6 (20.0%)               2 (7.4%)
  Cirrhosis (radiology)                        30 (100%)               27 (100%)
  Bilirubin, μM                                16.9 ± 9.4              22.5 ± 11.6
  Albumin, g/L                                 39.0 ± 6.9              37.4 ± 5.3
  AST, U/L                                     74.9 ± 102.3            83.5 ± 54.1
  ALT, U/L                                     54.1 ± 80.4             67.3 ± 43.5
  AFP, \>400 ng/mL                             9 (30.0%)               15 (55.6%)
  Child-Pugh class, A/B                        27/3 (90.0%/10.0%)      25/2 (92.6%/7.4%)
  The size of largest tumor (cm)               9.2 (range 5.0--13.6)   10.3 (range 5.0--14.6)
   Tumor \>10 cm                               14 (46.7%)              15 (55.6%)
   Tumor 5\~10 cm                              16 (53.3%)              12 (44.4%)
  Multifocal tumors in 1 lobe                  8 (26.7%)               12 (44.4%)
  Multifocal tumors in 2 lobes                 8 (26.7%)               12 (44.4%)
  BCLC stage                                                           
   B                                           19 (63.3%)              18 (66.7%)
   C                                           11 (36.7%)              9 (33.3%)
  Macrovascular invasion                       5 (16.7%)               4 (14.8%)
   The right branch of portal vein             4 (13.3%)               2 (7.4%)
   Hepatic vein                                --                      1 (3.7%)
   The right branch of portal + hepatic vein   1 (3.3%)                1 (3.7%)
  Extra-hepatic metastasis                     8 (26.7%)               8 (29.6%)
   Lung                                        1 (3.3%)                6 (22.2%)
   Lung + bone                                 1 (3.3%)                0 (0%)
   Soft tissue                                 --                      0 (0%)
   Lymph nodes                                 5 (12.2%)               0 (0%)
   Bone                                        1 (2.0%)                1 (3.7%)
   Bone+lymph node                             --                      1 (3.7%)

HBV, hepatitis B virius;.

HCV, hepatitis C virius;.

AST, Aspartate transaminase;.

ALT, Alanine aminotransferase;.

AFP, alpha-feto-protein.

###### Geometric means of viable tumor residues after treatment of cTACE or TILA-TACE in the nonrandomized cohort of 57 patients.

                                 Geometric mean (95% CI)                        
  ------------------------------ ------------------------- -------------------- ----------
  Crude VTR                      45.1% (30.3%--67.0%)      7.1% (4.4%--11.5%)   \<0.0001
  Multivariable adjusted VTR\*   45.6% (28.9%--72.0%)      7.1% (4.6%--10.9%)   \<0.0001

VTR: viable tumor residues;.

cTACE: transarterial chemoembolization;.

TILA-TACE: targeting-intratumoral-lactic-acidosis TACE;.

\*Adjusted for viable tumor volume prior to treatment and macrovascular invasion using the general linear regression. No appreciable alterations in results were found after adjustment for other covariates such as age, BCLC tumor stage, extra-hepatic metastasis, HBV DNA copy numbers, and tumor multifocality.

The geometric mean of VTR after the first treatment was 45.1% (95% CI: 30.3%--67.0%) in the cTACE group, significantly greater than that in the TILA-TACE (7.1% \[95% CI: 4.4%--11.5%\]; p\<0.0001) ([Table 2](#table2){ref-type="table"} and [Figure 1](#fig1){ref-type="fig"}). We further evaluated whether treatment effects (VTR) were confounded by some covariates such as age, BCLC tumor stage, extra-hepatic metastasis, HBV DNA copy numbers, viable tumor volume before treatment, macrovascular invasion, and tumor multifocality using general linear models. In this study, none of these clinical covariates were significantly associated with VTR (data not shown). Adjustment of these variables did not appreciably alter the results ([Table 2](#table2){ref-type="table"}). We then calculated the relative therapeutic improvement by TILA-TACE as described in Materials and methods. TILA-TACE achieved a 81.1% therapeutic improvement relative to cTACE.

![Viable tumor residues (VTR) after treatment of cTACE verus TILA-TACE.\
Patients' demographic parameters were described in [Table 1](#table1){ref-type="table"}. The relative therapeutic improvement by TILA-TACE was 81.1%. Relative therapeutic improvement by bicarbonate is defined as \[(μ~1~-μ~2~)/μ~1~\] × (100%), where μ~1~ is the mean of viable tumor residues after treatment (cTACE) and μ~2~ the mean residual after treatment (TILA-TACE), and the maximal therapeutic improvement is 100%. Differences in VTR between two groups were statistically significant (p\<0.0001), as assessed using the general linear model after adjustment for viable tumor volume before treatment\
Figure 1---source data 1.Calculation of viable volume residues of each patient in the nonrandomized study after the first round treatment.](elife-15691-fig1){#fig1}

We also categorized tumor responses to treatment into four categories from complete response (CR) to progressive disease (PD) according to EASL criteria. Complete or partial responses to treatment in the TILA-TACE group were significantly higher than that in the cTACE group. The percentage of CR, PR, SD, and PD in the cTACE group was 0%, 44.4%, 33.3%, and 22.2% ([Figure 2A](#fig2){ref-type="fig"}), respectively, compared with 23%, 77%, 0%, and 0%, respectively, in the TILA-TACE group ([Figure 2B](#fig2){ref-type="fig"}). The total objective response rate (complete or partial responses) in the cTACE group was 44.4%, whereas it was 100% in the TILA-TACE group ([Figure 2C](#fig2){ref-type="fig"}). The observed greater responses to treatment in the TILA-TACE than in the cTACE persisted after accounting for tumor volume prior to treatment using the proportional odds model (p\<0.0001).

![Tumor objective response to cTACE or TILA-TACE categorized according to EASL criteria.\
Rate of tumor response to treatment and representative MRI images of tumor before and after treatment (**A**) in the cTACE group (n=27) and (**B**) in the TILA-TACE group (n=30). (**C**) The difference in tumor responses between two groups was statistically significant (p\<0.0001), as assessed by the proportional odds model after adjustment for viable tumor volume before treatment. CR, complete necrosis; PR, viable tumor volume less than 50% of the viable tumor volume before treatment; SD, viable tumor volume larger than 50% of the viable tumor volume before treatment; PD, viable tumor volume larger than 100% after treatment.\
Figure 2---source data 1.The criteria and classification of response to treatment in the nonrandomized study after the first round treatment.](elife-15691-fig2){#fig2}

Because of the marked therapeutic improvement by TILA-TACE, the sample size required for the subsequent RCT to evaluate tumor responses to treatment was rather small. When patient number was 10 for each group, the estimated power value reached 0.826. In 2014, we recruited and randomly assigned twenty patients with large HCC (5.0 -- 13.5 cm) into cTACE (n=10) or TILA-TACE (n=10). Again, most of the selected clinicopathologic characteristics were well matched between two treatment groups ([Table 3](#table3){ref-type="table"}). After completion of the first treatment, the VTR in the TILA-TACE group was 5.5-fold lower than that in the cTACE group (4.6% \[95% CI: 1.8%--11.4%\] vs. 25.4% \[95% CI: 10.1%--64.0%\]; p=0.008) ([Figure 3](#fig3){ref-type="fig"} and Table 4). We also evaluated whether the treatment effect was confounded by aforementioned clinical parameters in the RCT. Among them, only viable tumor volume before treatment was significantly associated with VTR. Adjustment for tumor volume before treatment slightly changed the results, with the VTR in the TILA-TACE of 4.1% (2.0%--8.4%) vs. 28.1% (13.9%--56.8%) in the cTACE (p=0.0009). The relative therapeutic improvement by bicarbonate in the RCT was 80.1%, similar to that observed in the non-randomized cohort, 81.1%.

  Variables                          Patients                
  ---------------------------------- ----------------------- -----------------------
  Patient number                     10                      10
  Median age, years                  58 (Range 40--86)       53 (43--81)
  Gender (M/F)                       9 /1 (90.0%/10.0%)      7 /3 (70.0%/ 30.0%)
  Aetiology                                                  
   HBV                               9 (90.0%)               8 (80.0%)
   HCV                               0 (0%)                  0 (0%)
   Non B-non C                       1 (10.0%)               2 (20.0%)
  Cirrhosis (radiology)              10 (100%)               10 (100%)
  Bilirubin, μM                      17.2 ± 10.1             16.7 ± 7.6
  Albumin, g/L                       38.7 ± 3.1              38.1 ± 5.2
  AST, U/L                           64.8 ± 44.8             52.8 ± 19.2
  ALT, U/L                           60.6 ± 48.0             41.0 ± 29.9
  AFP, \>400 ng/mL                   3 (30.0%)               4 (40.0%)
  Child-Pugh class, A/B              10/0 (100%/0%)          10/0 (100%/0%)
  The size of largest tumor (cm)     7.9 (range 5.0--13.5)   7.5 (range 5.0--13.0)
   Tumor \>10 cm                     3 (30.0%)               3 (30.0%)
   Tumor 5\~10 cm                    7 (70.0%)               7 (70.0%)
  Multifocal tumors in 1 lobe        3 (30.0%)               3 (30.0%)
  Multifocal tumors in 2 lobes       4 (40.0%)               2 (20.0%)
  BCLC stage                                                 
   B                                 7 (70.0%)               8 (70.0%)
   C                                 3 (30.0%)               2 (20.0%)
  Macrovascular invasion             2 (20.0%)               1 (10.0%)
   The right branch of portal vein   1 (10.0%)               1 (10.0%)
   The left branch of portal vein    1 (10.0%)               0 (0%)
  Extra-hepatic metastasis           1 (10.0%)               2 (20.0%)
   Brain                             0 (0%)                  1 (10.0%)
   Lymph nodes                       1 (10.0%)               1 (10.0%)

HBV, hepatitis B virius;.

HCV, hepatitis C virius;.

AST, Aspartate transaminase;.

ALT, Alanine aminotransferase;.

AFP, alpha-feto-protein.

![Viable tumor residues after treatment with cTACE or TILA-TACE in the randomized controlled study.\
The relative therapeutic improvement by TILA-TACE was 80.1%. Differences in VTR between two arms were statistically significant (p=0.0009), as assessed using the general linear model after adjustment for viable tumor volume before treatment.\
Figure 3---source data 1.Calculation of viable volume residues of each patient in the randomized study after the first round treatment.](elife-15691-fig3){#fig3}

###### Geometric means of viable tumor residues after treatment of cTACE or TILA-TACE in the RCT.

                                 Geometric mean (95% CI)                       
  ------------------------------ ------------------------- ------------------- --------
  Crude VTR                      25.4% (10.1%--64.0%)      4.6 (1.8%--11.4%)   0.008
  Multivariable adjusted VTR\*   28.1% (13.9%--56.8%)      4.1 (2.0%--8.4%)    0.0009

VTR: viable tumor residues;.

cTACE: transarterial chemoembolization;.

TILA-TACE: targeting-intratumoral-lactic-acidosis TACE;.

RCT: randomized clinical trial.

\*Adjusted for viable tumor volume prior to treatment using the general linear regression. No appreciable alterations in results were found after adjusting for other covariates such as age, BCLC tumor stage, extra-hepatic metastasis, HBV DNA copy numbers, macrovascular invasion, and tumor multifocality individually.

If assessed by tumor objective response rate according to the EASL criteria, in TILA-TACE group, out of 12 targeted tumors, 4 achieved CR and 8 PR ([Figure 4](#fig4){ref-type="fig"}), whereas in cTACE group, out of 11 targeted tumors, 1 achieved CR, 6 PR, 2 SD, and 2 PD ([Figure 4](#fig4){ref-type="fig"}), with *P* value of 0.003 after adjustment for tumor volume prior to treatment. A similar result was found when assessing treatment effects for the largest tumor (p=0.003). In this RCT, the ORR in TILA-TACE group was 100% and the ORR in cTACE group was 63.6%.

![Tumor objective response to cTACE or TILA-TACE according to EASL criteria.\
Twenty patients were randomly assigned to treatment of cTACE or TILA-TACE. (**A**) Tumor response rate to cTACE and representative MRI images of tumor before and after treatment. 10 patients were treated with cTACE. (**B**) Tumor response rate to TILA-TACE and representative MRI image of tumor before and after treatment. 10 patients were treated with TILA-TACE. (**C**) The pattern of tumor response to TILA-TACE and cTACE. The difference between 2 groups was statistically significant (p=0.003), as assessed using proportional odds model. CR, complete necrosis; PR, viable tumor volume less than 50% of the viable tumor volume before treatment; SD, viable tumor volume larger than 50% of the viable tumor volume before treatment; PD, viable tumor volume larger than 100% after treatment.\
Figure 4---source data 1.The criteria and classification of response to treatment in the randomized study after the first round treatment.](elife-15691-fig4){#fig4}

Overall survival {#s2-2}
----------------

In the nonrandomized cohort of study, the 1-, 2-, 3-year survival of 27 patients treated with cTACE retrieved from our database were 66.7% (95% CI 45.7%--81.1%), 40.7% (95% CI 22.5%--58.2%), and 25.9% (95% CI 11.5%--43.1%), respectively, with a median survival of 14 months ([Figure 5A](#fig5){ref-type="fig"}), and the 1-, 2-, 3-year survival of 30 patients treated with TILA-TACE were 82.8% (95% CI 63.4%--92.8%), 67.7% (95% CI 47.0%--81.8%), and 61.8% (95% CI 39.7%--77.8%), respectively, with a median survival beyond 41 months ([Figure 5A](#fig5){ref-type="fig"}). The survival difference between TILA-TACE and cTACE was statistically significant (p=0.0052).

![Kaplan-meier analysis of cumulative survival of patients receiving TILA-TACE or cTACE treatment.\
(**A**) Cumulative survival of patients described in [Table 1](#table1){ref-type="table"}. p=0.0052. (**B**) Survival of patients described in [Table 2](#table2){ref-type="table"}. Left panel, all patients; right panel, patients who initially assigned to cTACE but subsequently crossed over to TILA-TACE treatment were excluded. p\>0.05. (**C**) Cumulative Survival of patients pooled from [Table 1](#table1){ref-type="table"} and [2](#table2){ref-type="table"}. p=0.0133.\
Figure 5---source data 1.The survival status of each patient at the cut-off date in the nonrandomized and the randomized studies.](elife-15691-fig5){#fig5}

In the randomized study, 4 patients initially assigned in and treated with cTACE group subsequently requested to cross over to TILA-TACE treatment. Although the cross-over was ethically warranted, this somehow blurred the overall survival difference between cTACE and TILA-TACE ([Figure 5B](#fig5){ref-type="fig"}). In cTACE group, 3 deaths occurred in 6 patients who solely received cTACE treatment, and 4 patients who initially received cTACE treatment and subsequently crossed over to TILA-TACE treatment were alive. In TILA-TACE group of 10 patients, 3 deaths occurred and 7 patients live. There was no apparent difference in overall survival between two treatment groups in the intent-to-treat (ITT) analysis ([Figure 5B](#fig5){ref-type="fig"}, left panel). However, a survival advantage appears in TILA-TACE treatment over cTACE treatment in the per-protocol (PP) analysis ([Figure 5B](#fig5){ref-type="fig"}, right panel), but statistically not significant. Overall, the RCT was limited by the small sample size and the result of the PP analysis was potentially confounded by the crossover of patients from cTACE group to TILA-TACE.

After pooling all patients together, there was a significant difference of survival between cTACE and TILA-TACE group ([Figure 5C](#fig5){ref-type="fig"}).

Adverse effects {#s2-3}
---------------

The adverse effect between cTACE and TILA-TACE group were comparable ([Tables 5](#table5){ref-type="table"} and [6](#table6){ref-type="table"}).

###### Adverse events of patients receiving TILA-TACE or cTACE.

  Adverse events\*       TILA-TACE      cTACE^†^
  ---------------------- -------------- -------------
  **Pain**               5 out of 30    3 out of 27
  **Fever (≥38.5)^‡^**   13 out of 30   9 out of 27

\* The adverse events monitored also include acute hepatic decomposition, irreversible hepatic decompensation, respiratory failure or decompensation, biliary stricture or obstruction, liver abscess, gastrointestinal bleeding, arterial thrombosis, arterial-portal shunting. These events were not observed in the patients.

^†^ Patients were retrospectively retrieved from our database.

^‡^ Mild fever occurred to all patients.

###### Adverse events in patients in the RCT.

  Adverse events\*       TILA-TACE     cTACE
  ---------------------- ------------- -------------
  **Pain**               2 out of 10   1 out of 10
  **Fever (≥38.5)^†^**   2 out of 10   3 out of 10

\* The adverse events monitored also include acute hepatic decomposition, irreversible hepatic decompensation, respiratory failure or decompensation, biliary stricture or obstruction, liver abscess, gastrointestinal bleeding, arterial thrombosis, arterial-portal shunting. These events were not observed in the patients.

^†^ Mild fever occurred to all patients.

Discussion {#s3}
==========

In this clinical investigation, we carried out 2 studies sequentially, the first one is a nonrandomized controlled study, which demonstrated a remarkable therapeutic improvement of TILA-TACE, based on which, a randomized controlled study was designed and carried out, and again it demonstrated a superior anticancer activity of TILA-TACE. The most striking point is that the numbers reflecting the therapeutic improvements by TILA-TACE from the 2 studies were nearly identical (81.1% and 80.1%). This confirms the consistency of anticancer activities of cTACE as well as TILA-TACE with respect to local control of large HCC.

We compared the ORR in our cTACE practice with those reported globally. The average objective tumor response to TACE is 35% (range, 16%--61%), as systematically reviewed by LIovet and Bruix for the Barcelona-Clinic Liver Cancer Group in 2002 ([@bib17]). In 2012, Forner, LIovet, and Bruix summarized that more than 50% of patients had an objective response to TACE ([@bib7]), suggesting that the objective tumor response to TACE in the 10-year period (2002--2012) had been increased for about 15%. The complete tumor response to TACE is rare (0-4.8%) ([@bib12]). Obviously, the results obtained from our cTACE practice were similar to those reported globally.

TACE is for local control of the targeted tumor. Many previous studies have confirmed that better local control was an independent prognostic indicator for patient survival ([@bib15]; [@bib13]; [@bib14]; [@bib26]; [@bib23]; [@bib9]; [@bib22]). Kim et al and Shim et al ([@bib15]; [@bib26]) further demonstrated a clear prognostic difference between CR, PR, stable disease and progressive disease. The current study demonstrated that TILA-TACE achieved a remarkable improvement of local tumor control and suggested an early sign of improved survival for patients with large HCCs ([Figure 5A](#fig5){ref-type="fig"}). It is noted that, during follow up, 16 patients in the TILA-TACE arm ([Figure 5A](#fig5){ref-type="fig"}), eventually exhibited progressive disease, including 11 patients with new foci in the liver, 1 with new liver foci and lung metastasis, and 3 with lung metastasis, and 1 with bone metastasis, all of which may account for the death ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). These observations suggest that fast CR and timely control of recurrent tumors in the liver would likely improve the survival of patients, especially those with large tumor burden and low liver reserve.

Nevertheless, the work is limited by the study design. The randomized controlled study designed in this investigation was for local tumor control, not for survival. Although the small sample size allowed us to evaluate the local tumor control, we did not expect that such small sample size would yield statistically significant data for cumulative survival. Evaluation of survival is a matter much more complicated than evaluation of local control. There are many more factors affecting the survival of patients than those affecting the local tumor control, e.g., tumor characteristics, liver function reserve, tumor staging, disease complications, vascular invasion, metastasis, etc., all of which must be well controlled. While we acknowledged these limitations of the present small RCT, the preliminary survival data allowed us to rationally calculate the sample size for a subsequent large RCT for evaluating the survival difference between cTACE and TILA-TACE. We are planning a large-scale RCT to further confirm the therapeutic advantage of TILA-TACE with respect to overall and progression-free survival of patients with large HCCs.

There was no significant difference of adverse effect between TILA-TACE and cTACE ([Tables 3](#table3){ref-type="table"} and [4](#table4){ref-type="table"}), i.e., TILA-TACE was as tolerable as cATCE. It was within our expectation, as locally administration of bicarbonate into tumor is safe.

Taken together, this pilot study demonstrated that bicarbonate infusion locally into HCC can markedly enhance anticancer activity of TACE, supporting the notion that neutralizing intratumoral lactic acidosis combined with glucose deprivation may deliver an effective approach to control tumor.

Materials and methods {#s4}
=====================

Patients and study design {#s4-1}
-------------------------

The study was performed with patients' written informed consent and with the approval of hospital's Institutional Review Board. Patients' consent to publish is obtained. The study is composed of 2 parts (Reporting standard 1). In the first part, twenty seven patients treated with cTACE were retrospectively retrieved (February 2010 -- March 2012) ([Supplementary file 1](#supp1){ref-type="supplementary-material"}) and the viable tumor residues were calculated, and 30 patients (January 2012 -- September 2013) ([Supplementary file 2](#supp2){ref-type="supplementary-material"}) with large HCC were recruited and treated with TILA-TACE (targeting-intratumoral-lactic-acidosis TACE, in this modality, bicarbonate was infused into tumor to neutralizing intratumoral lactic acidosis). In the second part, the data generated from part 1 were used to estimate the sample size for a subsequent randomized controlled study. Twenty patients (March 2014 -- August 2014) ([Supplementary file 3](#supp3){ref-type="supplementary-material"}) were randomly assigned to either TILA-TACE or cTACE treatment with ratio 1:1 (registration number: ChiCTR-IOR-14005319 in Chinense Clinical Trial Registry; protocol \[[Supplementary file 5](#supp5){ref-type="supplementary-material"}\] can be accessed at <http://www.medresman.org/>), according to the method of random number table. Patient inclusion criteria are: a diagnosis of HCC based on EASL or histological evidence, *Barcelona* Clinic Liver Cancer (BCLC) stage B or C, Child-pugh A or B, adult patients of age ≥ 20, hypervascular lesion as evaluated by triphasic MRI and *digital* subtraction angiography (DSA). Patient exclusion criteria are: BCLC stage 0, A or D, Child pugh C, evidence of combined A-V shunt.

Sample size calculation in the RCT {#s4-2}
----------------------------------

Sample size calculation was determined by the values of power and alpha: power (0.8) and alpha (0.05) can properly tell the statistical significance and minimize the number of patients to receive false choice of therapy. In order to calculate sample size for RCT, we calculate the viable tumor residues of 30 patients treated with TILA-TACE and 27 patients treated with cTACE as described below (Evaluation of tumor response, Calculation of total tumor volume, viable tumor volume, and necrotic tumor volume). Based on these data, we assessed the minimal number of patients required in a subsequent RCT. We assume the probability of making a Type I error to be 0.05 (α, two-sided), and the probability of making a Type II error to be 0.20 (β level), so the power of this RCT is 0.8 (1-β). The sample size was calculated according to Schouten's general formula:$$n_{1}\  \geq \ \left( z_{1 - \frac{\alpha}{2}} + z_{\beta} \right)^{2}\,\frac{\left( \tau + \gamma \right)\sigma_{1}^{2}}{\gamma\left( \mu_{1} - \mu_{2} \right)^{2}} + \frac{\left( \tau^{2}\, + \,\gamma^{3} \right)z_{1 - \alpha/2}^{2}}{2\gamma\left( \tau + \gamma \right)^{2}}$$

Where n~1~ and n~2~ represent the number of patients assigned to cTACE and TILA-TACE group, γ=n~1~/n~2~, μ~1~ (cTACE) and μ~2~ (TILA-TACE) is the mean viable tumor residues, and σ~1~ and σ~2~ are the corresponding standard deviation, τ=σ~2~^2^~/~σ~1~^2^, and Z is the normal deviate for alternative hypothesis at a level of significance. In practice, we used PASS software (version 11) to calculate the power and sample size, using the parameters mentioned above. As can been seen in [Supplementary file 4](#supp4){ref-type="supplementary-material"}, 9 patients in each group already satisfy the power and alpha value. For a pilot study, the sample size of 10 patients for each group was appropriate, as the estimated power value reached 0.826. Twenty patients were randomly allocated in a ratio of 1:1 to each group for the RCT.

Primary endpoint and secondary endpoint {#s4-3}
---------------------------------------

As the study was designed for observing the local tumor control, the primary endpoint was tumor objective response rate to the first treatment, measured by viable tumor residue (VTR), and the secondary endpoint was the overall survival.

Definition of relative therapeutic improvement {#s4-4}
----------------------------------------------

Relative therapeutic improvement by bicarbonate is defined as \[(μ~1~-μ~2~)/μ~1~\] × (100%), where μ~1~ is the mean percentage of viable tumor residues after treatment (cTACE) and μ~2~ the mean percentage of viable tumor residues after treatment (TILA-TACE). The maximum therapeutic improvement is 100%.

Quantitative calculation of viable tumor residues after treatment {#s4-5}
-----------------------------------------------------------------

The enhanced area and nonenhanced area in every slice of a tumor (2 mm thichness of each image if scanned by 3.0T MRI Discovery 750, GE Medical Systems or 3.5 mm thichness of each image if scanned by 3.0T MRI Signa Excite HD,GE Medical Systems), which was confirmed by 2 radiologists, was integrated according to MIPAV software ([@bib20]) (<http://mipav.cit.nih.gov/>). Summation of integrated enhanced and nonenhanced area of all slices of a tumor gave the viable and necrotic volumes of a tumor. Total tumor volume was the sum of viable and necrotic volume.

Viable tumors were assessed by MRI according to EASL criteria. The enhanced and non-enhanced areas represent viable and necrotic tumors. MRI examinations were performed on a 3.0T MRI (Signa Excite HD,GE Medical Systems,USA) or 3.0T MRI (Discovery 750, GE Medical Systems, USA). We assessed the necrotic and non-necrotic volume using T1 post gadolinium. In some cases, when the T1 post gadolinium image of the lesions did not show typical enhancement, we confirmed these lesions using imaging sequence of DWI and T2W.

The parameters of 3.0T MRI (Signa Excite HD,GE Medical Systems，USA) were as follows: T1WI fast gradient echo sequence TR/TE 180/2.4, FOV 40 × 36 cm, slice thickness 7 mm; T2WI fast spin echo sequence, TR/TE 6000/104.2, FOV 40 × 28 cm, slice thickness 7 mm; DWI single-shot spin-echo echo-planar imaging, SS-SE-EP, b value 600 sec/mm^2^, TR/TE 1300/52.3, FOV 40 × 40 cm, slice thickness 7 mm; Dynamic contrast-enhanced LAVA sequence, inversion time 5.0 s, TR/TE 2.7/1.3, FOV 40 × 40 cm; slice thickness 4 mm.

The parameters of 3.0T MRI (Discovery 750, GE Medical Systems, USA) were: T1WI fast gradient echo sequence, TR/TE 4.2/1.9, FOV 36 36 cm, slice thickness 4 mm; T2WI fast spin echo sequence, TR/TE 6666/65.3, FOV 36 × 36 cm, slice thickness 5 mm; DWI single-shot spin-echo echo-planar imaging, SS-SE-EP, b value 800 sec/mm^2^, TR/TE 6000/53.1; FOV 36 × 36 cm, slice thickness 5 mm; Dynamic contrast-enhanced LAVA sequence, inversion time 5.0 s, TR/TE 3.8/1.6, FOV 36 × 36 cm, slice thickness 4 mm.

European association for the study of the liver (EASL) criteria of tumor response to treatment {#s4-6}
----------------------------------------------------------------------------------------------

The targeted-tumor response to treatment was assessed 30 days after the first treatment according to EASL criteria ([@bib2]) and defined as below: complete response (CR), no obvious viable residues; partial response (PR), viable residues \<50%; stable disease (SD), viable tumor residues between \>50% but ≤100%; and progressive disease (PD), viable tumors \>100%.

Overall survival {#s4-7}
----------------

Overall survival was measured from the date of the first treatment until the date of death or the final follow up visit.

Treatment {#s4-8}
---------

TILA-TACE was performed through the transfemoral route using a 5-Fr catheter (Shepherd-hook modified Angiographic Catheter, HANACO Medical, Tian Jin, China) that was advanced to celiac artery. The tumor feeding arteries were defined by digital subtraction angiography. Then, a coaxial microcatheter (2.8 Fr Marguerite II, ASAHI INTECC GMA CO., LTD, Nagoya, Japan) was selectively inserted through a 5-Fr catheter into the tumor feeding artery, into which, 5% sodium bicarbonate (5% Sodium Bicarbonate Injection, Hunan Kelun Pharmaceutical, Ltd., Hunan, China) was infused alternatively with doxorubicin-lipiodol emulsion and oxaliplatin/homocamptothecin with the dose adjusted to tumor size . The dose of bicarbonate ranged between 50 and 250 ml corresponding to tumor sizes between 5 and 14 cm. Finally, the artery was permanently embolized with PVA of proper sizes (Embosphere, BioSphere Medical, Paris, France) and microcoil (Tornado, COOK Medical, USA).

The following example may give a clearer description of the procedure:

If a tumor (10 cm) is to be treated, according to our experience, we would prepare 150 ml 5% bicarbonate, 60 ml lipiodol doxorubicin emulsion (40 mg doxorubicin dissolved in 30 ml contrast medium and mixed with 30 ml lipiodol), oxaliplatin 150 mg in 20 ml 5% glucose, 40 mg homocamptothecin in 20 ml saline, PVA particles (100--300, 300--500, 500--700, or 700--900 μm), and microcoil. The TILA-TACE procedure would be as follows

1.  Superselectively identify all tumor feeding arteries.

2.  Estimate roughly the tumor volume covered by each tumor feeding artery. If there are 3 tumor feeding arteries, divide bicarbonate, doxorubicin-lipiodol emulsion, oxaliplatin, homocamptothecin into 3 parts. If they cover nearly the same volume of tumor, then divide the agents into 3 equal parts. If this is the case, the procedures will be as below:

3.  In each tumor feeding artery, about 25 ml bicarbonate would be injected into tumor feeding artery.

4.  Then, 3 ml doxorubicin-lipiodol emulsion, 1 ml oxaliplatin, 1 ml homocamptothecin, 3 ml bicarbonate, 20--40 PVA particles (PVA particle size would be chosen according to the diameter of artery), are sequentially injected.

5.  Repeat step 4 until the tumor supported by this artery is totally filled (lipiodol oil injection was monitored under fluoroscopic guidance). This cycle may repeat several times.

6.  Embolize the tumor feeding artery using PVA of suitable size to block blood stream. Microcoil is used to prevent washout of lipiodol by blood stream, if the diameter of the tumor feeding artery is large, e.g., the internal diameter is larger than 2 mm.

7.  The fully occlusion of feeding artery is confirmed by DSA angiography. The deposit of lipiodol oil was assessed by C-arm CT.

8.  Repeat step 3 to 7 on the second and the third feeding artery.

cTACE was performed the same as above, except no bicarbonate.

Retreatment was based on the evidence of viable tumor residues. The average sessions of treatment were 4 (range 1--13).

Adverse events {#s4-9}
--------------

The following adverse events which might occur during and after TACE procedure were monitored: blood pressure and oxygen saturation during TACE, pain, fever, and signs of liver decompensation after treatment, and biliary system.

Statistical analysis {#s4-10}
--------------------

Differences in viable tumor residues after the first treatment (the primary endpoint of the study) between the two treatment groups cTACE and TILA-TACE were examined using unpaired *t*-tests and were further adjusted for viable tumor volume before treatment and other potential confounding factors using the general linear model. Log-transformation was conducted to normalize the distribution of viable tumor residues and viable tumor volume before treatment in parametric analyses, with assigning 1 to viable tumor residues if the measured value (ranging 0--216.5%) was 0. We also categorized tumor responses to treatment into four categories according to EASL criteria. Differences in the distribution of categories of tumor responses to treatment between two treatment groups were examined using the proportional odds model after adjustment for viable tumor volume before treatment. Overall survival time was calculated from the date of the first treatment to the date of death from any cause or the last follow-up visit (October 31, 2015). Distributions of overall survival were charted by Kaplan-Meier method and compared with the log-rank test. The overall survival in the RCT was assessed using both the intent-to-treat and per-protocol methods. A two-sided alpha of 0.05 was used for all tests.
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Decision letter

Dang

Chi Van

Reviewing Editor

University of Pennsylvania

United States

In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

Thank you for submitting your article \"Intratumoral lactic acidosis is a promising therapeutic target for cancer therapy\" for consideration by *eLife*. Your article has been favorably evaluated by Charles Sawyers as the Senior editor and four reviewers, including Robert Gatenby and Chi Dang, who is a member of our Board of Reviewing Editors.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

In this manuscript, the authors report that local bicarbonate infusion prior to transarterial chemoembolization (TACE) of large hepatocellular carcinomas (HCCs) resulted in remarkable improvement in tumor responses in a nonrandomized cohort of 57 patients followed by a randomized control 20 patients, which supported the findings of the nonrandomized study. Specifically, the clinical responses with bicarbonate were remarkable with early signs of improved survival for patients with large HCCs. The authors speculated that reducing or \"targeting\" intra-tumoral lactic acidosis may improve the clinical outcome and reported an objective response rate of 100% in the therapy group vs. 44% in the control group. The authors conclude that bicarbonate local infusion markedly enhances the anticancer activity of TACE. If validated, this approach could be a significant improvement over current TACE and support the notion that cancer metabolism, and in this case -- acidity, could be manipulated in the clinic. While the data are of significant interest, there are some major concerns that must be addressed.

Essential revisions:

1\) The authors should provide additional details on the clinical protocol for administration of bicarbonate and subsequent chemoembolization so that others could reproduce the study. It is not clear whether and how the area and timing of the \"local bicarbonate\" injection and TACE overlaps to account for the therapeutic advantages. Since both local bicarbonate injection and TACE are both local treatments, how these two local treatments are related to each other are critical information that are missing from this manuscript.

2\) In the TACE group, were the patients treated with a placebo, such as saline injection to control for the placebo or procedure-related events that contribute to the differences in outcomes?

3\) The control arm with TACE alone achieved a survival of only 14 months, which is far below the expected survival outcomes available in the literature and various treatment guidelines. This may be due to the fact that both BCLC B and C patients were enrolled, which by itself is adding confusion to the interpretation of the data.

4\) The authors report a 100% response rate using EASL. If this was the case, the expected survival should really be much greater in the experimental arm. The authors do not make any comments on this fact. In addition, they do not report whether the tumors recurred or whether the patients had to be re-treated. These are critically important clinical questions that the authors must address. The sample sizes appear small to reach confident conclusions. Additional supplemental data files on the individual patients would add significantly and document the data in more detail. The statistical analysis needs much more details in terms of the local control benefit and how to correct for the patients\' cross-over between the two treatment groups.

5\) Given the complexity of the sample recruitment and group changing during the trial, CONSORT Flow Diagram and checklist will be important and helpful to make the data more transparent and interpretable.

10.7554/eLife.15691.sa2

Author response

> Essential revisions:
>
> 1\) The authors should provide additional details on the clinical protocol for administration of bicarbonate and subsequent chemoembolization so that others could reproduce the study. It is not clear whether and how the area and timing of the \"local bicarbonate\" injection and TACE overlaps to account for the therapeutic advantages. Since both local bicarbonate injection and TACE are both local treatments, how these two local treatments are related to each other are critical information that are missing from this manuscript.

We added a detailed protocol of TILA-TACE in the Methods section:

"The following example may give a clearer description of the procedure:

If a tumor (10 cm) is to be treated, according to our experience, we would prepare 150 ml 5% bicarbonate, 60 ml lipiodol doxorubicin emulsion (40 mg doxorubicin dissolved in 30 ml contrast medium and mixed with 30 ml lipiodol), oxaliplatin 150 mg in 20 ml 5% glucose, 40 mg homocamptothecin in 20 ml saline, PVA particles (100-300, 300-500, or 500-700,700-900 μm), and microcoil.

\[...\]

8\. Repeat step 3 to 7 on the second and the third tumor feeding artery."

> 2\) In the TACE group, were the patients treated with a placebo, such as saline injection to control for the placebo or procedure-related events that contribute to the differences in outcomes?

We agree with the reviewers' comment that the control group should have been treated with placebo (saline), but in this case, we did not use saline as placebo, because saline injection will change our standard cTACE protocol that we performed for years. If we add saline into the procedure, then the comparison would not be between TILA-TACE and standard cTACE.

In addition to the mechanism by which bicarbonate enhances the anticancer activity of TACE described in our manuscript, there is another mechanism that bicarbonate could enhance the anticancer activity of TACE. As the weakly basic doxorubicin is more toxic in basic pH than in acidic pH condition, intratumoral alkalization by bicarbonate would potentiate the cytotoxicity of doxorubicin. This is a critical point that should be clarified. Therefore, we initiated another small randomized controlled study (Title: Randomized controlled study of bicarbonate-enhanced transarterial chemoembolization and transarterial embolization in treatment of hepatocellular carcinoma; registration number ChiCTR-IPR-15006025 in Chinese Clinical Trial Registry), in which, patients were randomly assigned to TILA-TACE or TILA-TAE (transarterial embolization, the same as TILA-TACE, except no chemotherapeutic agents). So far, 36 patients have been treated, and the objective tumor response rates between TILA-TACE and TILA-TAE group were virtually the same. The study is ongoing, but the results achieved so far strongly suggest that bicarbonate is the major agent that results in massive death of HCC, because chemotherapeutic agents (with or without) did not make a significant difference (100% objective response rate (ORR) of the targeted tumors in the TILA-TACE arm versus 93% ORR of the targeted tumors in the TILA-TAE arm).

Although the above evidence cannot directly answer the question as to whether the same amount of saline injection would exert a similar effect to bicarbonate, it demonstrated that local bicarbonate injection into HCC is effective in control of the tumor.

> 3\) The control arm with TACE alone achieved a survival of only 14 months, which is far below the expected survival outcomes available in the literature and various treatment guidelines. This may be due to the fact that both BCLC B and C patients were enrolled, which by itself is adding confusion to the interpretation of the data.

The control arm with cTACE treatment achieved a median survival of 14 months. At the first glance, the median survival seems short. However, after close analysis, this median survival is most probably not below the expected survival outcome, if the patients' disease characteristics, particularly BCLC staging and tumor size, are taken into consideration. In this control arm, 27 HCC patients included 9 BCLC C and 18 BCLC B, among which there were 15 patients with tumor size larger than 10 cm and 3 patients with tumor size close to 10 cm (9.4, 9.1, and 8.6 cm). We did not find a paper that reported survival of patients with disease characteristics comparable to the patients in our study, but we may take the reported survival data of patients with different tumor stages and tumor size as references, as detailed below:

Overall survival wise, TACE is more effective for patients with less tumor burden and higher liver reserve than those with higher tumor burden and lower liver reserve (Sieghart et al., 2015; Llovet et al., 2002; Lo et al., 2002; Malagari et al., 2012; Burrel et al., 2012; Takayasu et al., 2012) e.g., the 3-year survival rates for ideal TACE candidates (low tumor burden at BCLC stage A or BCLC stage B) could reach 55%-65% (Malagari et al, 2012; Burrel et al., 2012; Takayasu et al., 2012) whereas the 3-year survival rates for less rigorously selected patients were only 26 -- 29% (Llovet et al., 2002; Lo et al., 2002). The 3 year survival of the control arm in this current study was 25.9%.

Tumor size appears to be a major factor to affect survival. LIovet et al. (2002) reported a 30 months median survival of patients at BCLC B and C with tumor size between 4.0 -- 5.8 cm; Lo et al. (2002) reported a 17 months median survival of patients at BCLC B and C with tumor size between 4.0 -- 14 cm; Huang et al. (2006) Jing-Huan Li (2015), and Paul et al. (2011) reported 9-10 months median survival of patients at BCLC B and C with tumor size larger than 10 cm.

For HCC patients at BCLC C stage, the recommended treatment is sorafenib. Current situation for patients with advanced HCC is desperate. Sorafenib is recommended for treating patients of BCLC C category. Two landmark studies confirmed that sorafenib could prolong modestly the median survival of patients in comparison to placebo (Cheng et al., 2009; Llovet et al., 2008). Cheng et al. reported a median survival of 6.5 months (sorafenib arm) versus 4.2 (placebo), and LIovet et al. reported a median survival of 10.7 months (sorafenib arm) and 7.9 months (placebo). The median survival of 10.7 months in the sorafenib arm was reproduced by several studies (Cheng et al., 2013; Cainap et al., 2015; Johnson et al., 2013).

If the references listed above and the disease characteristics of the patients in our study were taken into consideration, the median survival time of the patients in the control arm of the current study may be not worse than the reported ones.

References:

1\) Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002; 359(9319): 1734-9.

2\) Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002; 35(5): 1164-71.

3\) Malagari K, Pomoni M, Moschouris H, Bouma E, Koskinas J, Stefaniotou A, et al. Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. Cardiovasc Intervent Radiol. 2012; 35(5): 1119-28.

4\) Burrel M, Reig M, Forner A, Barrufet M, de Lope CR, Tremosini S, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol. 2012; 56(6): 1330-5.

5\) Takayasu K, Arii S, Kudo M, Ichida T, Matsui O, Izumi N, et al. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. J Hepatol. 2012; 56(4): 886-92.

6\) Huang YH, Wu JC, Chen SC, Chen CH, Chiang JH, Huo TI, et al. Survival benefit of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma larger than 10 cm in diameter. Alimentary pharmacology & therapeutics. 2006; 23(1): 129-35.

7\) Li JH, Xie XY, Zhang L, Le F, Ge NL, Li LX, et al. Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma. World journal of gastroenterology. 2015; 21(13): 3970-7.

8\) Paul SB, Gamanagatti S, Sreenivas V, Chandrashekhara SH, Mukund A, Gulati MS, et al. Trans-arterial chemoembolization (TACE) in patients with unresectable Hepatocellular carcinoma: Experience from a tertiary care centre in India. The Indian journal of radiology & imaging. 2011; 21(2): 113-20.

9\) Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10(1): 25-34.

10\) Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4): 378-90.

11\) Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2013; 31(32): 4067-75.

12\) Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, et al. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2015; 33(2): 172-9.

13\) Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2013; 31(28): 3517-24.

> 4\) The authors report a 100% response rate using EASL. If this was the case, the expected survival should really be much greater in the experimental arm. The authors do not make any comments on this fact.

The 100% ORR in the TILA-TACE group includes CR and PR of the targeted tumors. Many previous studies have confirmed that better local control was an independent prognostic indicator for patient survival (Kim et al., 2015; Shim et al., 2012; Jung et al., 2013; Kim et al., 2013; Riaz et al., 2011; Gillmore et al., 2011; Riaz et al., 2010), and Kim et al. (2015) and Shim et al (2012) further demonstrated that there was a clear prognostic difference between CR, PR, SD, and PD and that PR patients showed a significantly poorer survival than CR patients. Moreover, in the follow up, 16 patients eventually exhibited progressive disease, including 11 patients with new foci in the liver, 1 with new liver foci and lung metastasis, and 3 with lung metastasis, and 1 with bone metastasis, all of which accounted for the death in the experimental arm (Supplementary file 2). These observations also suggest that fast CR and timely control of recurrent tumors in the liver would likely improve the survival of patients, especially those with large tumor burden and low liver reserve. We also mentioned it in the Discussion section of the revised manuscript (third paragraph).

> In addition, they do not report whether the tumors recurred or whether the patients had to be re-treated. These are critically important clinical questions that the authors must address.

In the follow up, 16 patients ultimately exhibited progressive disease, including 11 patients with new foci in the liver, 1 with new liver foci and lung metastasis, and 3 with lung metastasis, and 1 with bone metastasis. We added the information into the revised manuscript (Discussion section, third paragraph, and Supplementary files 1--3).

In the Methods section, we added "Retreatment was based on the evidence of viable tumor residues. The average sessions of treatment were 4 (range 1-13)".

> The sample sizes appear small to reach confident conclusions. Additional supplemental data files on the individual patients would add significantly and document the data in more detail.

We added Supplementary files 1--3, which provide detailed information of the patients.

> The statistical analysis needs much more details in terms of the local control benefit and how to correct for the patients\' cross-over between the two treatment groups.

In the non-randomized cohort of the study, patients recruited in the treatment and control groups differed in some clinicopathological characteristics, although the same inclusion/exclusion criteria were used. In the revised manuscript, we evaluated whether treatment effects (assessed by viable tumor residues, VTR) were confounded by these clinical parameters such as age, BCLC tumor stage, extra-hepatic metastasis, HBV DNA copy numbers, viable tumor volume before treatment, macrovascular invasion, and tumor multifocality using general linear models. Among them, only viable tumor volume before treatment was significantly associated with VTR. We also found a similar association for macrovascular invasion, being of statistically borderline significance. Therefore, we adjusted for these two covariates and estimated multivariable-adjusted VTR using the general linear model. We found that adjustment for these potential confounding factors did not materially alter the results, suggesting that the finding of remarkable improvement in tumor responses in the TILA-TACE vs. cTACE was independent of patients' clinicopathological characteristics.

We also used the proportional odds model to adjust for viable tumor volume before treatment when comparing differences in the distribution of categories of tumor responses to treatment between two treatment groups.

The overall survival in the RCT was assessed using both the intent-to-treat (ITT) and per-protocal (PP) methods. There was no apparent difference in overall survival between two treatment groups in the ITT analysis. However, a survival advantage appears in TILA-TACE treatment over cTACE treatment in the PP analysis. PP analyses may provide a better sense of the actual biological effect of treatment but are like to introduce biases to the study because of abolishment of randomization. We acknowledged these limitations of the present small RCT in the revised manuscript. We are planning a large-scale RCT to further examine both targeted/local tumor responses, overall and progression-free survival with bicarbonate TACE in patients with large HCCs.

We added the information into in the revised manuscript (Methods, subsection "Statistical analysis", and Results section).

> 5\) Given the complexity of the sample recruitment and group changing during the trial, CONSORT Flow Diagram and checklist will be important and helpful to make the data more transparent and interpretable.

We added a CONSORT Flow Diagram (Reporting standard 1) and a CONSORT-checklist (Reporting standard 2).
